Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 21,996 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
Interventions: Durvalumab, Carboplatin, Pemetrexed, Paclitaxel, Cisplatin, AVENIO ctDNA Surveillance Kit, Tremelimumab; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Infant, Intubation Complication
Interventions: Personalized Intubation Safety (PINS) Bundle; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 1 Year
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Little Rock, Arkansas • Denver, Colorado • New Haven, Connecticut + 4 more

Conditions: Loudness Hyperacusis, Autism Spectrum Disorder (ASD), Hyperacusis
Interventions: Transitional Intervention for Hyperacusis in Autism; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 39 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Orlando, Florida • Dallas, Texas

Conditions: Adenoid Cystic Carcinoma
Interventions: Enfortumab Vedotin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Congestive Heart Failure(CHF), Pleural Effusion Due to Congestive Heart Failure
Interventions: Thoracentesis; Procedure
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Albany, New York

Conditions: Rhinovirus
Interventions: Nasal Swab Healthy Surveillance, Nasal Swab Sick Samples, Nasal Swab Hospitalized Cohort, Sick Follow-up Survey, Older Cohort Control Group, Procedural Comfort or Care; Diagnostic Test · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 17 Years
Enrollment: 670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions: pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cytomegalovirus Infections
Interventions: Not listed
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Preterm Birth, Preeclampsia
Interventions: Daily aspirin (ASA), Split dose aspirin (ASA); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 16 Years to 55 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Phobia, Social
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Brain Tumor - Metastatic
Interventions: Carmustine 7.7Mg Wafer; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Detroit, Michigan • Omaha, Nebraska

Conditions: Pain, Dementia
Interventions: Pain-CPG-EIT, Pain-CPG-Education Only; Behavioral · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 5 more

Conditions: Hepatic Insufficiency
Interventions: LY3841136; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Interventions: Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan, Trastuzumab deruxtecan; Device · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Voice Disorders, Vocal Fold Polyp, Vocal Nodules in Adults, Muscle Tension Dysphonia
Interventions: Ambulatory Voice Monitoring with Biofeedback (AVM-B), Conversation Training Therapy; Device · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: LungTrainers, LungTrainers Pulmonary Rehabilitation regime; Device · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: 24-hydroxylase Deficiency
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Failure and Reduced Ejection Fraction
Interventions: Online, patient-facing decision-making aid (app) with personalized risk information., Implantable Cardioverter Defibrillator (ICD), Online, patient-facing decision-making app without personalized risk information.; Other · Device
Lead sponsor: Stanford University; Other
Eligibility: 60 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: San Francisco, California • Greenville, North Carolina

Conditions: Lymphedema
Interventions: GLP-1 Receptor Agonists; Drug
Lead sponsor: Advanced Reconstructive Surgery Alliance; Government
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Red Bank, New Jersey • Westwood, New Jersey

Conditions: HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride; Drug · Procedure
Lead sponsor: Laura Huppert, MD, BA; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Blood Pressure
Interventions: HemoSphere Vita Monitor with VitaWave or VitaWave Plus Finger Cuff Adult, and ForeSight Large Sensors; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Colorectal Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer
Interventions: Exercise Program; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cerebral Palsy
Interventions: Spinal Stimulation, Treadmill Walking; Device · Other
Lead sponsor: University of Washington; Other
Eligibility: 4 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Long Term Follow-up
Interventions: Non-interventional; Other
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: San Diego, California • Miami, Florida • Hillsborough, New Jersey

Search by objective public record fields.

Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

Optimizing Tracheal Intubation Outcomes and Neonatal Safety

Transitional Intervention for Hyperacusis in Autism

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

DRAIN: DRainage in Acute Decompensated Heart faIlure With Pleural effusioNs

The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)

Investigating the Effects of Cannabidiol on Social Anxiety Disorder

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Testing the Pain Clinical Practice Guideline

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

Scalp Cooling in MBC

Project 4: Ambulatory Biofeedback and Voice Therapy for Patients With Vocal Hyperfunction

Breathing Training and Exercise Capacity in Non-CFB

24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry

Developing a Digital Aid to Improve ICD Decisions

Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

The Continuity Study

Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial

Short-term Spinal Stimulation Effects in Cerebral Palsy

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)